Teva Pharmaceutical Industries Limited Receives European Marketing Authorization for Lonquex® (XM22 lipegfilgrastim)
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced today that the European Commission has granted marketing authorization for Lonquex® (lipegfilgrastim). This approval provides the regulatory framework for the commercialization of Lonquex® in all twenty eight countries of the European Union plus Norway, Iceland and Liechtenstein.
Help employers find you! Check out all the jobs and post your resume.
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced today that the European Commission has granted marketing authorization for Lonquex® (lipegfilgrastim). This approval provides the regulatory framework for the commercialization of Lonquex® in all twenty eight countries of the European Union plus Norway, Iceland and Liechtenstein.
Help employers find you! Check out all the jobs and post your resume.